Novartis to advance malaria program into PhIII in bid to fight drug resistance
Novartis is moving an anti-malaria drug into a Phase III trial that it hopes could provide a new weapon against drug-resistant strains of the infection.
The company and its Swiss non-profit partner Medicines for Malaria Venture, or MMV, announced Wednesday that they are moving forward with the treatment, which uses the experimental drug ganaplacide combined with a new formulation of current anti-malaria drug lumefantrine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.